Zolpidem, Triazolam, and Temazepam: Behavioral and Subject-Rated Effects in Normal Volunteers
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Zolpidem is an imidazopyridine hypnotic that is biochemically distinct from classic benzodiazepine agonists in that it may be selective for the BZ1 receptor subtype and shows a different pattern of distribution of binding sites. The present study compared the learning, recall, performance, subject-rated and observer-rated effects of zolpidem, triazolam, and temazepam in 11 healthy humans. Placebo, zolpidem (5, 10, and 20 mg/70 kg), triazolam (0.125, 0.25, and 0.50 mg/70 kg), and temazepam (15, 30, and 60 mg/70 kg) were administered orally in a randomized, double-blind, cross-over design. Zolpidem, triazolam, and temazepam produced orderly dose- and time-related impairment of learning, recall, and performance, and increased subject- and observer-rated estimates of strength of drug effect. The absolute magnitude of these effects at peak effect were comparable across the three compounds. The time to maximal drug effect was faster with zolpidem (0.5-1.0 hours) than with triazolam (1.5-2.0 hours) or temazepam (2-3 hours). These results suggest that despite the somewhat unique benzodiazepine receptor-binding profile of zolpidem, its behavioral and subject-rated effects are similar to those of benzodiazepine hypnotics (i.e., triazolam and temazepam).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Sannerud, C. A., Ator, N. A., & Brady, J. V. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11429-8 · Cited by 112
Self-citationInvestigation of the development of tolerance to the actions of zolpidem and midazolam
Sanger, D. J., & Zivkovic, B. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90172-9 · Cited by 47
Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone
Byrnes, J. J., Greenblatt, D. J., & Miller, L. G. (1992) · Brain Research Bulletin · doi:10.1016/0361-9230(92)90164-s · Cited by 46
Cited by
Zolpidem: A Review of Its Use in the Management of Insomnia
Swainston Harrison, T., & Keating, G. M. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00008 · Cited by 323
Holm, K. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200059040-00014 · Cited by 317
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia
Zammit, G. K., McNabb, L. J., Caron, J., Amato, D. A., & Roth, T. (2004) · Current Medical Research and Opinion · doi:10.1185/174234304x15174 · Cited by 294
Greenblatt, D. J., & Roth, T. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.667074 · Cited by 283
Residual Effects of Hypnotics: Epidemiology and Clinical Implications
Vermeeren, A. (2004) · CNS Drugs · doi:10.2165/00023210-200418050-00003 · Cited by 277
Metadata
- Authors
- Rush, C. R., & Griffiths, R. R.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1996-04
- Volume
- 16
- Issue
- 2
- Pages
- 146-157
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2010503474
- Cited by
- 97
- References
- 3
- FWCI
- 17.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zolpidem, Triazolam, and Temazepam: Behavioral and Subject-Rated Effects in Normal Volunteers. https://app.cochat.ai/papers/10.1097/00004714-199604000-00007
- The paper
- Rush, C. R., & Griffiths, R. R. (1996). Zolpidem, Triazolam, and Temazepam: Behavioral and Subject-Rated Effects in Normal Volunteers. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199604000-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.